Business Description
Elite Pharmaceuticals Inc
NAICS : 325412
SIC : 2833
ISIN : US28659T2006
Description
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.84 | |||||
| Equity-to-Asset | 0.54 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -2.84 | |||||
| Interest Coverage | 17.29 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 7.63 | |||||
| Beneish M-Score | -1.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.8 | |||||
| 3-Year EBITDA Growth Rate | -30.7 | |||||
| 3-Year EPS without NRI Growth Rate | 125.7 | |||||
| 3-Year Book Growth Rate | 50 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.37 | |||||
| 9-Day RSI | 42.89 | |||||
| 14-Day RSI | 45.99 | |||||
| 6-1 Month Momentum % | 238.16 | |||||
| 12-1 Month Momentum % | 340.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.52 | |||||
| Quick Ratio | 2.42 | |||||
| Cash Ratio | 0.74 | |||||
| Days Inventory | 130.77 | |||||
| Days Sales Outstanding | 90.15 | |||||
| Days Payable | 25.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | -0.31 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.73 | |||||
| Operating Margin % | 20.53 | |||||
| Net Margin % | -8.98 | |||||
| FCF Margin % | 3.5 | |||||
| ROE % | -12.54 | |||||
| ROA % | -7.88 | |||||
| ROIC % | 21.96 | |||||
| ROC (Joel Greenblatt) % | -17.37 | |||||
| ROCE % | -9.06 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio without NRI | 183.33 | |||||
| PS Ratio | 8.21 | |||||
| PB Ratio | 12.5 | |||||
| Price-to-Tangible-Book | 13.75 | |||||
| Price-to-Free-Cash-Flow | 275 | |||||
| Price-to-Operating-Cash-Flow | 137.5 | |||||
| EV-to-EBIT | -99.38 | |||||
| EV-to-EBITDA | -146.89 | |||||
| EV-to-Revenue | 8.28 | |||||
| EV-to-FCF | 236.18 | |||||
| Price-to-Projected-FCF | 17.84 | |||||
| Price-to-Median-PS-Value | 1.27 | |||||
| Price-to-Graham-Number | 10.7 | |||||
| Earnings Yield (Greenblatt) % | -1.01 | |||||
| FCF Yield % | 0.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ELTP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Elite Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 71.171 | ||
| EPS (TTM) ($) | -0.008 | ||
| Beta | 0.11 | ||
| Volatility % | 78.17 | ||
| 14-Day RSI | 45.99 | ||
| 14-Day ATR ($) | 0.046762 | ||
| 20-Day SMA ($) | 0.566447 | ||
| 12-1 Month Momentum % | 340.57 | ||
| 52-Week Range ($) | 0.1213 - 0.7549 | ||
| Shares Outstanding (Mil) | 1,068.27 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Elite Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Elite Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Elite Pharmaceuticals Inc Frequently Asked Questions
What is Elite Pharmaceuticals Inc(ELTP)'s stock price today?
The current price of ELTP is $0.54. The 52 week high of ELTP is $0.75 and 52 week low is $0.12.
When is next earnings date of Elite Pharmaceuticals Inc(ELTP)?
The next earnings date of Elite Pharmaceuticals Inc(ELTP) is 2025-02-14 Est..
Does Elite Pharmaceuticals Inc(ELTP) pay dividends? If so, how much?
Elite Pharmaceuticals Inc(ELTP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers